Published Date: 20/09/2007
Category: Drug Delivery & Devices
Research Report Decription
This report gives in depth analysis of innovative drug delivery
technologies and devices that are being developed to defficiently deliver medicines which treat type I and/or type II diabetes. These include innovative delivery devices (reusable & disposable autoinjectors, needle free deivces) for systemic delivery and novel oral, buccal, intranasal, pulmonary and transdermal formulations of new and approved products to ease adminstration and improve patient compliance.
Key Questions Answered:
- How will the drug delivery technology drivers change in the diabetes arena during the next decade and beyond?
- What are the key delivery technologies and devices in the diabetes field?
- When are products and medical devices which utilize these key delivery technologies likely to reach the market?
- Which drug delivery technologies are likely to win in the near-term and the long-term, and why?
- Which companies are the winners in each technology category?
- How are drug delivery technologies evolving to meet the demands of the diabetes market?
- Where are the market opportunities now and in the future?
- What do we predict will be the value of the diabetes drug delivery and medical devices market each year until 2012, in 2015 and in 2020?
Access Pharmaceuticals, Aegis Therapeutics LLC, Alkermes, Altea Therapeutics, Alza Corporation, Amylin Pharmaceuticals Inc., Apollo Life Sciences, Aradigm, AVI BioPharma, Band & Olufsen Medicom, Baxter, Bentley Pharmaceuticals Inc, BioDel Inc., ConjuChem, Depomed Inc., Eiffel Technologies, Eli Lilly & Company, enGENE, Emisphere Technologies, Generex Biotechnology Corporation, Hubei Huagong Biochemical Engineering, Kos Pharmaceuticals, Innovata (Vectura Group plc), Insulet Corporation, Intarcia Therapeutics, Ipsen, Mannkind Corporation, Medtronic, Nanoderma Ltd, Nastech Pharmaceutical Co, Nektar Therapeutics, Novo Nordisk A/S, OraMed Pharmaceuticals, Pfizer, Phosphagenics Ltd, Roche, StratGent Life Sciences, The Medical House plc, TransPharma Medical, Valois
- 2006 global diabetes market worth around US$22 billion.
- This attracted attention of specialty pharma and big pharma players such as Bayer, Daiichi-Sankyo, GlaxoSmithKline, Eli-Lilly, Merck & Co., Novartis, Novo Nordisk, Pfizer, Sanofi-aventis and Takeda.
- Challenges remain to ensure the efficient delivery of insulin by invasive and non-invasive delivery methods to provide flexible, reproducible and cost-effective methods of managing diabetes.
- Analysis of historic (2000-2005) market trends of the anti-diabetic pharmaceutical sales and advanced drug delivery sales.
- Forecasts for near-term (2006-2012) and the future (2020) market growth based on the technology platforms evaluated in the report.
- Plus, sales forecasts for approved and pipeline diabetes products and medical devices.
- Specialists are applying a plethora of platforms to deliver insulin, including jet injectors, pulmonary, transdermal, buccal & nasal delivery systems.
- Many new classes of drugs will reach the market over the next 6 years, driving future market growth. Their success is analyzed in detail and case studies provided to highlight the progress of each technology.
- Medical devices continue to evolve with the aim todevelop an “artificial pancreas”, one which is capable of delivering & monitoring insulin blood levels on a minute by minute basis. A number of devices are evaluated in this report.
- As the diabetes market evolves new approaches to treatment of diabetes are emerging utilizing islet cell transplantation plus cell- and gene-based therapies. Several Biotherapeutics companies are working towards this goal including: AVI BioPharma, enGENE & TransitionTherapeutics. A number of delivery options are currently being evaluated to optimize the clinical utility of these regenerative therapies and are analyzed in detail in the report.